Abraxis BioScience, Inc. and Specialised Therapeutics Australia Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand  
7/29/2010 8:04:43 AM

LOS ANGELES & MELBOURNE, Australia--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.